Infection Research; a joint venture between the Hannover Medical School and the Abstract While antibiotics are intended to specifically target bacteria, most are known to affect host cell physiology. In addition, some antibiotic classes are reported as immunosuppressive, for reasons that remain unclear. Here we show that linezolid, a ribosomal-targeting antibiotic (RAbo), effectively blocked the course of a T cellmediated autoimmune disease. Linezolid and other RAbos were strong inhibitors of Th17 effector function in vitro, showing that this effect was independent of their antibiotic activity. Perturbing mitochondrial translation in differentiating T cells, either with RAbos or through the inhibition of mitochondrial elongation factor G1 (mEF-G1) progressively compromises the integrity of the electron transport chain (ETC). Ultimately, this leads to loss of mitochondrial metabolism and cytokine production in differentiating Th cells. In accordance, mice lacking Gfm1 in T cells are protected from EAE, demonstrating that this pathway plays a key role in maintaining T cell function and pathogenicity.
Introduction
Bacteria require intact cell walls and functional ribosomes to retain their structural and metabolic integrity. As such, inhibition of these processes by antibiotics either kills bacteria or prevents their growth and division (1-3). As eukaryotic cells do not possess cell walls and their ribosomes are structurally different from bacterial ribosomes, antibiotic drugs can be used in the clinic to eradicate bacterial infections, with limited toxicity to the host. Nevertheless, some antibiotics have reported side effects, such as candidiasis, anemia, bone marrow suppression, lactic acidosis and immunosuppression (4-11). Since antibiotics are often administered to patients who have ongoing bacterial infections, it is important to understand the mechanisms governing antibiotic-mediated immunosuppression. Without a proper host immune response, both clearance of infections and control of opportunistic pathogens are impaired. Strikingly, both the cellular and molecular mechanisms governing immunosuppression by antibiotics are poorly understood. Here, we focus on linezolid, a ribosomal-targeting antibiotic (RAbo) from the Oxazolidinone family which targets Grampositive bacteria (12) and has been approved (and is reserved) for treatment of several multi-resistant bacterial infections (13) . Patients requiring linezolid treatment often present in a critical state and are at increased risk of fungal infections, especially after prolonged administration (14) . Moreover, linezolid is associated with higher mortality by Gramnegative pathogens when compared with vancomycin. Both antibiotics share a similar spectrum of action, and therefore this discrepancy is unusual (15) .
Linezolid, unlike vancomycin, pertains to the class of RAbos, which have been shown to inhibit mitochondrial translation in mammalian systems and cell lines (16) (17) (18) . It achieves this by occupying the peptidyl transferase center at the 50S subunit of the mitochondrial ribosome, interfering with the binding of aminoacyl-tRNAs (19) . The correct assembly of electron transport chain (ETC) complexes relies on the coordinated translation of proteins which are simultaneously derived by cytosolic and mitochondrial ribosomes (20, 21) . By blocking mitoribosomes, RAbos can lead to an imbalance of nuclear and mitochondrialencoded ETC subunits (mitonuclear imbalance) (22) . The concept of mitonuclear imbalance and its relevance to organismal physiology has been previously explored in different fields of medical research. Specifically, inhibition of mitochondrial translation, which leads to a decrease in mitochondrial-encoded subunits, affects adipokine secretion in adipocytes (23), improves worm lifespan in C. elegans (22) , and selectively kills leukaemia cells (24) . The consequence of blocking mitochondrial protein synthesis in immune cells however, has not been elucidated.
Here, we show that linezolid exhibits strong immunosuppressant properties, as illustrated by its capacity to disrupt the development of self-reactive Th cells in a mouse model of multiple sclerosis. Linezolid and other RAbos were additionally able to directly inhibit Th17 function in vitro, showing that immunosuppression occurs independently of their antibiotic activity. Mechanistically, we demonstrate that inhibitors of mitochondrial translation lead to a mitonuclear imbalance in differentiating Th17 cells, which culminates in loss of mitochondrial activity and cytokine production. In conclusion, administration of RAbos should be carried out with extra caution to prevent undesired immunosuppression.
On the other hand repurposing of RAbos and/or development of novel drugs with a similar mechanism of action, could potentially be used to control T-cell mediated autoimmune disorders.
Linezolid inhibits onset of a T cell mediated autoimmune disease
To determine if Th17 cell responses in vivo could be altered by RAbos treatment, we explored a murine model of T-cell mediated autoimmunity, namely Experimental Autoimmune Encephalomyelitis (EAE). MOG-immunized mice develop severe, classical, clinical signs of EAE, presenting with infiltrating Th cells in the central nervous system (CNS), as well as decreased motility. However, administration of a human-equivalent dose of linezolid limited the development and severity of EAE symptoms (Fig. 1a, b ). This correlated with lower frequencies and numbers of infiltrating Th cells in the CNS of linezolid-treated mice (Fig. 1c) . Linezolid treatment led to a marked decrease in MOGspecific IL-17A-and IFN-γ-producing Th cells, without effects on the frequency of Foxp3 + Th cells. Oral antibiotics can lead to disturbances of microbial populations in the intestinal lumen, which in turn can influence the outcome of an immune response (25) (26) (27) . To rule out that any effects mediated by linezolid were due to its antibacterial activity, vancomycin was used as an additional control, which holds a similar spectrum of activity against bacteria as linezolid. Vancomycin-treated mice developed severe EAE symptoms comparable to those of the untreated group, strongly suggesting that linezolid's immunosuppression was due to its effect on host cells, and not bacterial cells.
Mitochondrial translation inhibition by antibiotics inhibits Th17 cell function
Linezolid was able to strongly inhibit EAE induction when compared to vancomycin, which prompted us to look at differences in their mechanism of action. While vancomycin inhibits cell wall synthesis in bacterial cells, linezolid works by inhibiting prokaryotic ribosomes, blocking bacterial protein synthesis. Because mitochondria are of prokaryotic origin, there are substantial similarities between bacterial and mitochondrial mRNA translation machinery (28). Consequently, some RAbos can also inhibit mitoribosomes. This is true not only for linezolid, but also for other antibiotics pertaining to different classes such as tigecycline (a Glycylcycline) and thiamphenicol (an Amphenicol) (29) (30) (31) .
Hence, we postulated that RAbos inhibited Th17 function independently of their antibiotic function, through inhibition of mitochondrial translation. In accordance, when murine naïve CD4 + T cells were cultured under Th17 polarizing conditions in the presence of the aforementioned antibiotics, their IL-17 production was reduced by all three drugs in a dosedependent manner ( Fig. 2a, above) . Importantly, loss of cytokine-producing cells was not caused by death of effector cells, as viability was mostly unaffected (Fig. 2a, below) . To verify that this effect was not exclusive to murine cells, we differentiated human cord blood-derived naïve T cells under Th17-polarizing conditions in the presence of linezolid. Accordingly, human Th17 cells equally presented a lower IL-17A secretion upon linezolid treatment (Fig. 2b, left) . Like in the murine system, viability was not affected at the indicated concentrations (Fig. 2b, right) . We sought to determine if linezolid was able to acutely inhibit mitochondrial translation in T cells. To this end, we labeled mitochondrial translation products with [ 35 S]-methionine in a murine lymphoma T cell line (EL-4), pretreated for 1h with linezolid. We observed a near complete blockage of [ 35 S]-methionine incorporation into mitochondrial-encoded ETC subunits by linezolid at 100µM ( Fig. 2c) , which correlated with the concentration required to fully inhibit IL-17 production ( Fig. 2a) .
The ETC is composed of five complexes, made up of several protein subunits, which must be correctly assembled in the inner mitochondrial membrane. While all complex II subunits are encoded in the nucleic DNA (nDNA) and translated in the cytosol, complexes I, III, IV and V contain subunits encoded by both nDNA and mitochondrial DNA (mtDNA).
Therefore, the assembly of these complexes requires a tight coordination between the cytosolic and mitochondrial protein machinery. When mitochondrial translation is exogenously interrupted, a mitonuclear imbalance occurs, as illustrated by a higher ratio of nDNA to mtDNA-encoded subunits (16, 22) . Accordingly, the presence of linezolid leads to the selective depletion of mtDNA-encoded mitochondrial-NADH-ubiquinone oxidoreductase chain 1 (ND1) and cytochrome C oxidase I (COX1) (Fig. 2d) . By contrast, the levels of nuclear-encoded succinate dehydrogenase complex flavoprotein subunit A (SDHA) remain unaffected ( Fig. 2d) . These findings confirm that mitoribosomes -but not cytosolic ribosomes -are targets of linezolid.
Argyrin C and linezolid exert analogous effects on differentiating Th17 cells
Mitochondrial ribosome subunits are encoded by the MT-RNR1 and MT-RNR2 genes, which encode the 12S and 16S ribosomal RNA (rRNA), respectively. These rRNAs differ between individuals, depending on their mitochondrial haplotype (32) (33) (34) . This has the potential to modulate the susceptibility of mitoribosomes to RAbos, as shown previously for linezolid (35). To explore different ways of inhibiting mitochondrial translation, we employed the Argyrin (Arg) family of compounds ( Fig. 3a and S1a). Argyrins do not bind to the mitoribosome, but instead to mitochondrial elongation factor G1 (mEF-G1) (36), an enzyme necessary for the elongation step during mitochondrial protein synthesis (37). The inhibitory capacities of the different Arg family members on Th17 cytokine production were quantified in cultured murine naïve CD4 + T cells under Th17 polarizing conditions ( Fig. S1a, b) . Arg A and B effectively inhibited the frequency of IL-17A-producing T cells only at the highest concentration (240nM) tested, while Arg C and D were effective at much lower doses (24nM). Notably, Arg F and G had no immunosuppressive activity at the tested concentrations despite holding high homology with the most active family members Arg C and D (Fig. S1b, left) . Importantly, Arg F still retained the capacity to inhibit IL-17 production, albeit at higher concentrations, (>600nM) (Fig. S1c, left) . This is consistent with a previous report, showing that Arg F inhibited COX2 expression at doses higher than 600nM (38). As we observed for RAbos, cellular viability was not affected by any Argyrin (Fig. S1b , right and S1c, right).
Considering the marked differences in the activity of each compound, we focused on the most active metabolite, Arg C, for further studies (Fig. 3a) . To assess whether Arg C exerts a general inhibitory effect on effector Th subset differentiation, we differentiated Th17, Th1
and Th2 under a broader range of Arg C concentrations. Addition of Arg C during mouse and human Th17 differentiation resulted in a dose dependent inhibition of the frequencies of IL-17A produced from these cells ( Fig. 3b, above) , without affecting their viability ( Fig.   3b , below). Cytokine production by murine Th1 and Th2 cells were also affected, with IFN-γ and IL-13 production being equally reduced by Arg C (Fig. S2a) . As expected, mEF-G1 inhibition by Arg C resulted in loss of mitochondrial translation, as measured by a near complete blockage of [ 35 S]-methionine incorporation in mtDNA-encoded subunits in Arg C-treated EL-4 cells (Fig. 3c) . A reduction of [ 35 S]-methionine incorporation was also detectable after Arg F pretreatment (60nM). However, this effect was partial and only observed at a concentration 100 times higher than required for a similar inhibition with Arg C. This correlated with the lack of cytokine inhibition by Arg F at 60nM (Fig S1b and c) .
Both linezolid and Arg C present as inhibitors of mitochondrial protein synthesis, despite their different molecular targets. To determine overall similarities between both drugs, we performed RNAseq analysis on Th17 cells exposed to linezolid, Arg C and DMSO.
Differential gene expression analysis showed most genes significantly up-or downregulated by linezolid were equally up-or downregulated by Arg C after 96h ( Fig.   3d ). Among the top downregulated pathways by both linezolid and Arg C, were those corresponding to glycolysis and Th cell differentiation ( Fig. 3e, f) . Noteworthy, pathways significantly upregulated in linezolid and Arg C were associated with cell cycle control and response to DNA damage ( Fig. 3e, f) . Importantly, genes downregulated by both linezolid and Arg C in the "T helper cell differentiation" pathway included several Th17-associated genes, such as Il17a, Il17f, Il23r, Rorc and Il21 (Fig. 3f) . Taken together, our results demonstrate a high degree of similarity between the effects of linezolid and Arg C on Th17 cells.
Proliferating T cells depend on functional mitoribosomes to maintain their ETC integrity and effector function
Naïve T cells have a lower proliferation rate, cellular respiration, and a decreased mitochondrial proteome when compared to activated T cells (39) (40) (41) (42) . T cell activation leads to several rounds of cell division, which requires the biogenesis of mitochondrial proteins.
We therefore postulated that activated T cells would have a higher requirement for newly synthesized ETC subunits, including those encoded by mtDNA. To assess the reliance of differentiating and naïve T cells on mitochondrial translation, we measured the intracellular content of ND1 and COX1 throughout a culture with Arg C. After 48h of treatment, both ND1 and COX1 levels sharply decreased exclusively in Arg C-treated differentiating Th17 cells. Arg F, at sub-inhibitory concentrations (60nM), failed to reduce the levels of either subunit (Fig. 4a, left) . Arg C, like linezolid, did not reduce the expression levels of the nuclear-encoded protein SDHA. Importantly, naïve T cells partially retained both COX1 and ND1 even after 120h of Arg C-treatment ( Fig. 4a, right) , showing that activated T cells are more sensitive to inhibition of this pathway than when maintained in a naïve state. Mitochondrial respiration has been described to support essential metabolic needs in proliferating cells through regeneration of electron accepting co-factors such as NAD + or FAD using oxygen as the terminal electron acceptor (43). Consistent with the findings from Sullivan et al (43), the impact of both Arg C and linezolid on mitochondrial respiration resulted in a decreased intracellular NAD + /NADH ratio after 48h ( Fig. 4b and S3a) . A reduced NAD + /NADH ratio leads to allosteric inhibition of the enzyme complex pyruvate dehydrogenase, which converts pyruvate into acetyl-CoA by decarboxylation. In these conditions, we speculated that pyruvate would preferentially be converted into lactate (24, 44, 45) . This hypothesis was corroborated by a drop in pH of the culture medium together with a slight increase in lactate production by Arg C-treated cells as compared to Arg F or DMSO ( Fig. S3b, c) . Deficient electron flow from the pyridine nucleotide NADH, to oxygen, together with a lack of mitochondrial-encoded subunits of complex V, F 1 F o -ATPase (namely ATP6 and ATP8), would hinder OXPHOS-derived ATP production. Accordingly, the ADP/ATP ratio was significantly increased in Arg C-treated cells compared to controls ( Fig. S3d) .
As expected, Arg C and linezolid-treated cells lost the ability to carry out mitochondrial respiration, illustrated by a lower basal and FCCP-stimulated maximal cellular respiration ( Fig. 4c, d) . Mitochondrial dysfunction by Arg C was also illustrated by electron microscopy imaging of differentiating Th17 cells. In contrast to the round shaped mitochondria characteristic of Th cells (40), Arg C treated cells presented elongated mitochondria with loosened cristae (Fig. 4e) . After 96h of culture, this resulted in sacshaped or swollen mitochondria, comparable to the morphology of this organelle in cells devoid of mitochondrial DNA (ρ 0 cells) (46). Similar to previous reports on ρ 0 cells (47), Arg C-treated cells were able to maintain a mitochondrial membrane potential ( Fig. S3e) .
Importantly, while loss of mtDNA-encoded subunits was evident at 48h, IL-17 production was only reduced at 72h ( Fig. 4f ). This suggested that initial differentiation steps were unaffected, as evidenced by the capacity for Arg C-treated cells to produce IL-17 until 48h.
To confirm this, we measured the expression of the Th17-cell master transcription factor RORγt. Indeed, Arg C did not affect expression of the transcription factors T-bet, or RORγt in Th1, Th2 and Th17 cells, respectively ( Fig. S4a-c ). This indicates that Arg C impairs cytokine production and not the initial Th cell transcriptional program.
Considering our transcriptomic data suggested cell cycle pathways to be dysregulated ( Fig.   3e , f) we investigated the relationship between proliferation and loss of cytokine production caused by Arg C. Using cells labelled with CellTrace TM we observed that proliferation under Arg C treatment was mildly impaired toward the final stages of differentiation ( Fig.   S4d ). Importantly, this moderate decline in cellular proliferation was not the main cause of cytokine inhibition, as all cells from across each individual cycle showed significantly reduced IL-17 production after 72h of culture ( Fig. S4e) . Therefore, Arg C's inhibitory effect on cytokine production is not merely a consequence of impaired cellular division of effector cells.
Gfm1 loss results in deficient mitochondrial translation and impaired Th17 effector function
Aside from targeting mitochondrial ribosomes, linezolid is also a weak inhibitor of monoamine oxidase (48). In addition, the Argyrins have also been described as inhibitors of the proteasome (49, 50) . To exclude that any of these alternative side effects were responsible for the immunosuppressive effects seen by these drugs, we genetically targeted mitochondrial protein synthesis in T cells. As the target of linezolid is the mitoribosome, which is encoded fully by mtDNA, we focused on Gfm1, the gene encoding mEF-G1, located on chromosome 3 (51). Given that ubiquitous deletion of Gfm1 is lethal at preweaning stages, we generated an inducible T cell specific Gfm1 deficient mouse strain (T-Gfm1Δ). Mice expressing a CD4-specific, tamoxifen-inducible Cre enzyme (Cd4Cre ERT2/wt ) were crossed with mice carrying a loxP-flanked exon 4 in the Gfm1 gene (Gfm1 flox/flox ) ( Fig. 5a) . In contrast to complete Gfm1 knockout mice, T-Gfm1Δ mice are viable and express normal levels of COX1 in their CD4 + T cells, indicative of functional mitochondrial translation ( Fig. 5b and S5a). Upon treatment with 4-hydroxytamoxifen (4-OHT), COX1 expression levels significantly dropped in CD4 + T cells from T-Gfm1Δ mice in comparison with those still harboring Gfm1 WT alleles, either in a haplo-sufficient form (Cd4Cre ERT2/wt Gfm1 flox/wt ) ( Fig. 5b) or lacking Cre-recombinase activity (Gfm1 flox/flox Cd4Cre wt/wt ) ( Fig. S5a) . Similar to Arg C, differentiation of 4-OHT-treated naïve T cells isolated from T-Gfm1Δ mice under Th17-skewing conditions yielded a significantly reduced frequency of IL-17A-expressing cells ( Fig. 5c, Fig. S5b ). Finally, we demonstrate that tamoxifen-mediated genetic deletion of Gfm1 in CD4 + cells in T-Gfm1Δ mice, leads to significant protection from the development of EAE. Mice retaining a functional Gfm1 allele in CD4 + T cells (Gfm1 flox/wt ) are more susceptible to symptoms of the disease (Fig. 5d) . Taken together, our results indicate that loss of mitochondrial translation in T cells, either genetically or pharmacologically, restrains Th17 function. We further show that mitochondrial translation is necessary for T cell pathogenicity in vivo and could represent a therapeutic target to halt Th cell aberrant responses.
Discussion
It is well established that some RAbos can inhibit mammalian mitochondrial ribosomes.
Furthermore, certain RAbos were previously described as immunosuppressive. For example, chloramphenicol diminishes neutrophil extracellular trap release and doxycycline inhibits B cell class switching and IgM secretion (52, 53). However, how the reduction of immune cell function occurred was mechanistically not well understood. We show here that inhibition of mitochondrial protein synthesis by antibiotics can reduce Th cell cytokine secretion. Certain clinical observations suggest that linezolid is immunosuppressive, even though this has never been officially proposed nor investigated. As previously mentioned, linezolid treatment is known to confer increased risk of fungal and gram-negative infections (14, 15) . Th17 cell function is necessary in mounting antifungal and antibacterial responses. Linezolid is active exclusively against gram-positive bacteria, and we postulate that linezolid facilitates opportunistic fungal or gram-negative infections by dampening Th17 function. Importantly, we found linezolid to inhibit both mitochondrial translation and Th17 cell function in vitro at concentrations routinely achieved during clinical administration (54). We show in a T cell-mediated autoimmunity model of multiple sclerosis (EAE) that linezolid prevents the development of self-reactive T cells. Thus, repurposing linezolid as an immunosuppressive drug resulted in significant protection from pathogenic T cell infiltration and led to absent (or mild) EAE symptoms, reflected by lower clinical scores. However, future studies will be necessary to determine if T cell-suppression by linezolid contributes to the progression of infections by gram-negative or fungal pathogens.
To further study the role of mitochondrial translation in T cells, we searched for alternative methods to inhibit this process. In light of the indispensable role of mEF-G1 in catalyzing the translocation of mitoribosomes during mitochondrial protein translation (37, 55), we made use of Arg C to hinder mEF-G1's activity during Th differentiation. Murine mEF-G1
shares 89% sequence identity with the human homologue mEF-G1 (51), and accordingly, Arg C was active against both human and mouse Th17 cells. The similarities in the gene transcriptional changes of Arg C-and linezolid-treated cells further confirm that targeting mitochondrial translation with either compound leads to analogous cellular effects. Using Arg C, we were able to determine that differentiating T cells are highly reliant on a functional mitochondrial protein synthesis machinery to keep up with ETC biosynthetic demands. Notably, although Arg C inhibited mitochondrial protein synthesis after 1h of treatment, the lack of mitochondrial-encoded and -translated ETC subunits was first evidenced after 48h of cell activation. At 24h the majority of cells have not yet proliferated (56) and, presumably, did not need to synthesize large amounts of new ETC subunits.
Between 24-48h, cell growth and division would require an increase in mitochondrial mass and proteome. Therefore, an impaired mitochondrial translation machinery would render cells unable to keep up with the cellular demand for an increased synthesis of ETC subunits. Ultimately, this would "dilute" pre-existing mitochondrial-encoded proteins such as COX1 and ND1 amongst daughter cells. Consequently, interfering with mitochondrial translation might be particularly detrimental for rapidly dividing cells such as activated T cells (57), while non-proliferative cells should be able to retain their ETC subunits for longer. Accordingly, we show that naïve T cells exposed to Arg C for as long as 120h still expressed both COX1 and ND1.
Activated CD4 + T cells in the presence of Arg C are subjected to a gradual loss of ETC integrity which leads to reduced oxygen consumption and a concomitant loss of electron acceptors such as NAD + . To circumvent this, the cell is forced to convert pyruvate into lactate. As fermentation of glucose into lactate does not yield net NAD + (39), over time the cofactor levels required to support essential oxidative steps in proliferating cells decrease.
Accordingly, Th17 cells treated with Arg C display both a reduced NAD + /NADH ratio, respiration and increased lactate secretion. Interestingly, inhibition of mitochondrial translation by Arg C did not influence mitochondrial membrane potential. In this respect, studies on cells lacking mtDNA, termed ρ°, revealed that these cells display a mitochondrial membrane potential high enough to sustain the import of nuclear-encoded proteins. The mechanism is thought to involve an electrogenic exchange of ATP 4for ADP 3by the adenine nucleotide carrier and maintained by an incomplete F 1 F o -ATPase (47, 58, 59) . This process would consume glycolysis-derived ATP and is in agreement with the strong increase of ADP/ATP ratio measured in Arg C-treated cells.
Upon activation, CD4 + T cells cycle must undergo several rounds of proliferation to develop into cytokine producing Th effector cells (60). While loss of COX1 and ND1 occurs at 48h, neither proliferation nor IL-17 production are affected at this time point.
Instead, we observe that if mitochondrial translation remains inhibited, cells progressively become unable to produce IL-17. The down regulation of cytokines becomes evident from 72h onwards, present simultaneously in cells from all individual proliferation cycles. This highlights that Arg C's cytokine inhibition and anti-proliferative phenotypes are uncoupled, and inhibition of proliferation per se cannot explain loss of IL-17 production. Arg C appears to strictly affect effector function, and not initial Th cell transcriptional programs. This is consistent with Arg C-treated Th1, Th2 and Th17 cells retaining their expression of master transcription factors T-bet, GATA-3 and RORߛt, respectively.
While our results might suggest the repurposing of antibiotics as immunomodulatory drugs, this might be a double-edged sword given a potential negative impact on gut flora (25, 61).
Of greater consequence, widespread usage of linezolid in an autoimmune setting might speed up the dissemination of resistant bacterial strains to this reserve antibiotic.
Alternatively, antibiotics which are not routinely used in human medicine, such as thiamphenicol, could be further explored as immunomodulators. Importantly, the Argyrins display poor antibacterial and antifungal properties and are not currently used as antibiotics in the clinic (62). Furthermore, inhibition of mEF-G1 by Arg C blocked mitochondrial translation in Th17 cells at concentrations 4-5 orders of magnitude lower than linezolid.
Even though we lacked the means to develop a good in vivo administration method for Arg C, we propose that further steps should be taken to adapt novel and more potent mitochondrial translation inhibitors for therapeutic use. To encourage such efforts, we investigated the role of mEF-G1 in Th17 cell function by generating an inducible T cell specific Gfm1 deficient mouse strain. Tamoxifen-mediated deletion validated that mEF-G1
is necessary for T cells to maintain their effector function in vitro. Moreover, specifically deleting Gfm1 in CD4 + cells at the onset period of EAE induction protected against disease symptoms and provided strong evidence that this pathway is necessary in vivo, for T cellmediated pathogenicity. Taken together, our results provide strong evidence to consider the inhibition of mitochondrial translation as a novel approach to halt pathological Th cell responses. Additionally, we identify mEF-G1 as a promising target to control this cellular process and achieve immunomodulation and highlight the ability of RAbos to alter host cell functions.
Methods
Mice. C57BL/6 mice were purchased from Jackson Laboratories. Gfm1 flox/flox were generated by crossing mice carrying the heterozygous Gfm1 tm1a(EUCOMM)Wtsi "knockout first" allele (purchased from EMMA mouse repository) with Flp-expressing mice to obtain the conditional allele (63). T-Gfm1Δ were generated by crossing Cd4Cre ERT2/wt (64) to Gfm1 phenotype, the medium was supplemented further with rhIL-1β (10 ng mL -1 , R&D Systems), rhIL-23 (20 ng mL -1 , R&D Systems), rhIL-6 (20 ng mL -1 ; Peprotech), rhIL-21 (20 ng mL -1 ; Peprotech), rhTGF-β1 (3 ng mL -1 ; Peprotech), α CD28 (500ng mL -1 ) and
20mM NaCl. Arg C and linezolid were added at the indicated concentrations from day 0.
Naïve T cell maintenance and Gfm1 deletion. Naïve T cells (CD4 + CD25 -CD62L+
CD44 low ) were sorted from spleens and lymph nodes of mice and maintained in RPMI 1640
GlutaMAX TM medium (from Life Technologies) supplemented with 10% heat-inactivated FCS (Biochrom), 1X Antibiotic Antimycotic Solution (Sigma) and 50 μ M β mercaptoethanol (Life Technologies), containing rmIL-7 (20ng mL -1 , Peprotech). rmIL-7 (10ng mL -1 ) was re-added at the 3 rd , 5 th , 7 th , 9 th and 11 th days of culture. To induce tamoxifen-mediated deletion in vitro, (Z)-4-Hydroxytamoxifen (Sigma) at 300nM was added at the beginning of the culture. After 12 days, naïve T cells were harvested, counted, and re-plated at a density of 1.5×10 5 cells per well under Th17-polarizing conditions as described above. For in vivo deletion of Gfm1 during EAE induction, mice were administered with a single dose of 2mg of Tamoxifen (Santa Cruz) dissolved in corn oil intraperitoneally, 3 days after EAE induction.
Flow cytometry. Monoclonal antibodies specific against the following mouse antigens were purchased from Affymetrix/eBioscience: CD4 (GK1.5), IL-17A (eBio17B7), IL-13 H2O (1:3) . The next day, UAR was removed by washing in H2O for 5 x 3 minutes. The cells were then incubated for 30 minutes in Walton's lead solution at 60ºC. After final washing steps the samples were dehydrated using increasing EtOH concentration (70%, 90%, 2x 100%), for 5 minutes each followed by 2 x 10 minutes of propylene oxide (Aldrich). Subsequent infiltration with resin (Spurr, EMS) was done by first incubating in 50% resin in propylene oxide for 2 hours, followed by at least 3 changes of fresh 100% resin (including 1 overnight incubation). Next, samples were embedded in fresh resin and cured in the oven at 65 °C for 72 hours. For FIB-SEM imaging, embedded cells were mounted on aluminium SEM stubs (diameter 12 mm) and samples were coated with ~8nm of Platinum (Quorum Q150T ES). FIB-SEM imaging was performed using a Zeiss Crossbeam 540 system with Atlas5 software. The Focussed Ion Beam (FIB) was set to remove 5nm sections by propelling Gallium ions at the surface.
Imaging was done at 1.5kV using an ESB (back-scattered electron) detector.
Dataset, quality control and RNA-seq analysis
The Raw FASTQ files were quality controlled, trimmed and mapped to the Mus musculus Animals were euthanized if score reached grade 3.5 for two consecutive days and subsequently scored as 5 the following days. To determine CNS infiltrates, mice were sacrificed at day 15 or 16 post-induction and cell suspensions from brain and spinal cord were prepared, as described previously (66). Single suspension of cells were cultured in 48well plates in the presence of 30 μ g mL -1 MOG of three (a,b) r  i  e  s  n  i  t  z  C  ,  B  e  c  k  e  r  T  .  P  a  t  h  w  a  y  s  t  o  b  a  l  a  n  c  e  m  i  t  o  c  h  o  n  d  r  i  a  l  t  r  a  n  s  l  a  t  i  o  n  a  n  d  p  r  o  t  e  i  n  i  m  p  o  r  t  .  G  e  n  e  s  &  d  e  v  e  l  o  p  m  e  n  t  .  2  0  1  8  ;  3  2  (  1  9  -2  0  )  :  1  2  8  5  -9  6  .  2  1  .  R  i  c  h  t  e  r  -D  e  n  n  e  r  l  e  i  n  R  ,  O  e  l  j  e  k  l  a  u  s  S  ,  L  o  r  e  n  z  i  I  ,  R  o  n  s  o  r  C  ,  B  a  r  e  t  h  B  ,  S  c  h  e  n  d  z  i  e  l  o  r  z  A  B  ,  e  t  a  l  .  M  i  t  o  c  h  o  n  d  r  i  a  l  P  r  o  t  e  i  n  S  y  n  t  h  e  s  i  s  A  d  a  p  t  s  t  o  I  n  f  l  u  x  o  f  N  u  c  l  e  a  r  -E  n  c  o  d  e  d  P  r  o  t  e  i T  s  u  b  o  i  M  ,  M  o  r  i  t  a  H  ,  N  o  z  a  k  i  Y  ,  A  k  a  m  a  K  ,  U  e  d  a  T  ,  I  t  o  K  ,  e  t  a  l  .  E  F  -G  2  m  t  i  s  a  n  e  x  c  l  u  s  i  v  e  r  e  c  y  c  l  i  n  g  f  a  c  t  o  r  i  n  m  a  m  m  a  l  i  a  n  m  i  t  o  c  h  o  n  d  r  i  a  l  p  r  o  t  e  i  n  s  y  n  t  h  e  s  i  s  .  M  o  l  e  c  u  l  a  r  c  e  l  l  .  2  0  0  9  ;  3  5  (  4  )  :  5  0  2  -1  0  .  3  8  .  C  h  e  n  X  ,  B  u  i  K  C  ,  B  a  r  a  t  S  ,  T  h  i  N  g  u  y  e  n  M  L  ,  B  o  z  k  o  P  ,  S  i  p  o  s  B  ,  e  t  a  l  .  T  h  e  r  a  p  e  u  t  i  c  e  f  f  e  c  t  s  o  f  A  r  g  y  r  i  n  F  i  n  p  a  n  c  r  e  a  t  i  c  a  d  e  n  o  c  a  r  c  i  n  o  m 
